IndraLab

Statements


| 2

reach
"Our previous research revealed that STAMBPL1, a deubiquitinase, promotes cisplatin resistance in TNBC by stabilizing MKP1 (Liu et al., 2022)."

reach
"Our previous research revealed that the deubiquitinase STAMBPL1 enhances the stability of MKP-1, thereby promoting cisplatin resistance in breast cancer."